Localization of Human Copper Transporter 1 in the Eye and its Role in Eales Disease

REFERENCES

• Goodman VL, Brewer GJ, Merajver SD. Copper deficiency as an anti-cancer strategy. Endocr Relat Cancer. 2004;11(2): 255–263.
   PubMed Web of Science ®Google Scholar
• Conforti A, Franco L, Milanino R, et al. Copper metabolism during acute inflammation: studies on liver and serum copper concentrations in normal and inflamed rats. Br J Pharmacol. 1983;79(1):45–52.
   PubMed Web of Science ®Google Scholar
• Hopkins RG, Failla ML, Copper Deficiency Reduces Interleukin-2(IL-2) Production and IL-2 mRNA in Human T-Lymphocytes. J Nutr. 1997;127(2):257–262.
   PubMed Web of Science ®Google Scholar
• Kennedy T, Ghio AJ, Reed W, et al. Copper-dependent inflammation and nuclear factor-kappaB activation by particulate air pollution. Am J Respir Cell Mol Biol. 1998;19(3): 366–378.
   PubMed Web of Science ®Google Scholar
• Gole GA, McAuslan BR, Ocular angiogenesis. Experimental models. Trans Ophthalmol Soc N Z. 1981;33:51–53.
   PubMedGoogle Scholar
• Hannan GN, McAuslan BR, Modulation of synthesis of specific proteins in endothelial cells by copper, cadmium, and disulfiram: an early response to an angiogenic inducer of cell migration. J Cell Physiol. 1982;111(2):207–212.
   PubMed Web of Science ®Google Scholar
• Ziche M, Jones J, Gullino PM. Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst. 1982;69(2):475–482.
   PubMed Web of Science ®Google Scholar
• Finney L, Vogt S, Fukai T, et al. Copper and angiogenesis: unravelling a relationship key to cancer progression. Clin Exp Pharmacol Physiol. 2009;36(1):88–94.
   PubMed Web of Science ®Google Scholar
• Banci L., Bertini I, Cantini F, et al. Cellular copper distribution: a mechanistic systems biology approach. Cell Mol Life Sci. 2010;67(15):2563–2589.
   PubMed Web of Science ®Google Scholar
• Ashino T, Sudhahar V, Urao N, et al. Unexpected role of the copper transporter ATP7A in PDGF-induced vascular smooth muscle cell migration. Circ Res. 2010;107(6):787–799.
   PubMed Web of Science ®Google Scholar
• Cai H. Wu JS, Muzik O, et al. Reduced 64Cu uptake and tumor growth inhibition by knockdown of human copper transporter 1 in xenograft mouse model of prostate cancer. Journal of Nuclear Medicine. 2014;55(4):622–628.
   PubMed Web of Science ®Google Scholar
• Brady DC, Crowe MS, Turski ML, et al. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature. 2014;509(7501):492–496.
   PubMed Web of Science ®Google Scholar
• Zimnicka AM, Tang H, Guo Q, et al. Upregulated copper transporters in hypoxia-induced pulmonary hypertension. PLoS One. 2014;9(3):e90544.
   Google Scholar
• Narayanan G, Bharathidevi SR, Vuyyuru H, et al. CTR1 silencing inhibits angiogenesis by limiting copper entry into endothelial cells. PLoS One. 2013;8(9):e71982.
   PubMed Web of Science ®Google Scholar
• Biswas J, Sharma T, Gopal L, et al. Eales disease–an update. Surv Ophthalmol. 2002;47(3):197–214.
   PubMed Web of Science ®Google Scholar
• Saxena S, Khanna V, Kumar D, et al. Enhanced oxidative stress in Eales disease. Ann Ophthalmol. 2001;33(1):40–42.
   Google Scholar
• Ramakrishnan S, Rajesh M, Sulochana KN. Eales’ disease: oxidant stress and weak antioxidant defence. Indian J Ophthalmol. 2007;55(2):95–102.
   PubMedGoogle Scholar
• Sen A, Paine SK, Chowdhury IH, et al. Impact of interleukin-6 promoter polymorphism and serum interleukin-6 level on the acute inflammation and neovascularization stages of patients with Eales’ disease. Mol Vis. 2011;17:2552–2563.
   PubMed Web of Science ®Google Scholar
• Saxena S, Pant AB, Khanna VK, et al. Tumor necrosis factor-alpha-mediated severity of idiopathic retinal periphlebitis in young adults (Eales’ disease): implication for anti-TNF-alpha therapy. J Ocul Biol Dis Infor. 2010;3(1):35–38.
   PubMedGoogle Scholar
• Letelier ME, S. Sanchez-Jofre, L. Peredo-Silva, et al. Mechanisms underlying iron and copper ions toxicity in biological systems: Pro-oxidant activity and protein-binding effects. Chem Biol Interact. 2010;188(1):220–227.
   PubMed Web of Science ®Google Scholar
• Pabla N, Murphy RF, Liu K, et al. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 2009;296(3):F505–F511.
   PubMed Web of Science ®Google Scholar
• Guo Y, Smith K, Petris MJ. Cisplatin stabilizes a multimeric complex of the human CTR1 copper transporter: requirement for the extracellular methionine-rich clusters. J Biol Chem. 2004;279(45):46393–46399.
   PubMed Web of Science ®Google Scholar
• Konerirajapuram NS, Coral K, Punitham R, et al. Trace elements iron, copper and zinc in vitreous of patients with various vitreoretinal diseases. Indian J Ophthalmol. 2004;52(2):145–148.
   PubMedGoogle Scholar
• Rajesh M, Sulochana KN, Punitham R, et al. Involvement of oxidative and nitrosative stress in promoting retinal vasculitis in patients with Eales’ disease. Clin Biochem. 2003;36(5):377–385.
   PubMed Web of Science ®Google Scholar
• Ward SK, Hoye EA, Talaat AM. The Global Responses of Mycobacterium tuberculosis to Physiological Levels of Copper. J Bacteriol. 2008;190(8):2939–2946.
   PubMed Web of Science ®Google Scholar
• Holzer AK, Varki NM, Le QT, et al. Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem. 2006;54(9):1041–1049.
   PubMed Web of Science ®Google Scholar
• Ugarte M, Osborne NN, Brown LA, et al. Iron, zinc, and copper in retinal physiology and disease. Surv Ophthalmol. 2013;58(6):585–609.
   PubMed Web of Science ®Google Scholar
• Kuo Y-M, Gybina AA, Pyatskowit JW, et al. Copper transport protein (Ctr1) levels in mice are tissue specific and dependent on copper status. J Nutr. 2006;136(1): 21–26.
   PubMed Web of Science ®Google Scholar
• Verma A, Biswas J, Radhakrishnan S, et al. Intra-ocular expression of vascular endothelial growth factor (VEGF) and pigment epithelial-derived factor (PEDF) in a case of Eales’ disease by immunohistochemical analysis: a case report. Int Ophthalmol. 2010;30(4):429–434.
   PubMedGoogle Scholar
• Davies KM, Hare DJ, Cottam V, et al. Localization of copper and copper transporters in the human brain. Metallomics. 2013;5(1):43–51.
   PubMed Web of Science ®Google Scholar
• Squitti R, Hoogenraad T, Brewer G, et al. Copper status in Alzheimer’s disease and other neurodegenerative disorders 2013. Int J Alzheimers Dis. 2013;2013:838274.
   PubMedGoogle Scholar
• Zheng Z, White C, Lee J, et al. Altered microglial copper homeostasis in a mouse model of Alzheimer’s disease. J Neurochem. 2010;114(6):1630–1638.
   PubMed Web of Science ®Google Scholar
• Wei H, Frei B, Beckman JS, et al. Copper chelation by tetrathiomolybdate inhibits lipopolysaccharide-induced inflammatory responses in vivo. Am J Physiol Heart Circ Physiol. 2011;301(3):H712–H720.
   Google Scholar
• Wei H, Zhang WJ, McMillen TS, et al. Copper chelation by tetrathiomolybdate inhibits vascular inflammation and atherosclerotic lesion development in apolipoprotein E-deficient mice. Atherosclerosis. 2012;223(2):306–313.
   PubMed Web of Science ®Google Scholar
• Rajesh M, Sulochana KN, Ramakrishnan S, et al. Iron chelation abrogates excessive formation of hydroxyl radicals and lipid peroxidation products in monocytes of patients with Eales’ disease: direct evidence using electron spin resonance spectroscopy. Curr Eye Res. 2004;28(6): 399–407.
   PubMed Web of Science ®Google Scholar
• Cui JZ, Wang XF, Hsu L, et al. Inflammation induced by photocoagulation laser is minimized by copper chelators. Lasers Med Sci. 2009;24(4):653–657.
   PubMed Web of Science ®Google Scholar